468 results on '"Ader, Florence"'
Search Results
52. A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity
- Author
-
Provoost, Judith, Valour, Florent, Gamondes, Delphine, Roux, Sandrine, Freymond, Nathalie, Perrot, Emilie, Souquet, Pierre-Jean, Kiakouama-Maleka, Lize, Chidiac, Christian, Lina, Gérard, Dumitrescu, Oana, Sénéchal, Agathe, and Ader, Florence
- Published
- 2018
- Full Text
- View/download PDF
53. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
- Author
-
Ader, Florence, primary, Bouscambert-Duchamp, Maude, additional, Hites, Maya, additional, Peiffer-Smadja, Nathan, additional, Poissy, Julien, additional, Belhadi, Drifa, additional, Diallo, Alpha, additional, Lê, Minh-Patrick, additional, Peytavin, Gilles, additional, Staub, Thérèse, additional, Greil, Richard, additional, Guedj, Jérémie, additional, Paiva, Jose-Artur, additional, Costagliola, Dominique, additional, Yazdanpanah, Yazdan, additional, Burdet, Charles, additional, Mentré, France, additional, Egle, Alexander, additional, Joannidis, Michael, additional, Lamprecht, Bernd, additional, Altdorfer, Antoine, additional, Belkhir, Leila, additional, Fraipont, Vincent, additional, Verschelden, Gil, additional, Aboab, Jérôme, additional, Ader, Florence, additional, Ait-Oufella, Hafid, additional, Andrejak, Claire, additional, Andreu, Pascal, additional, Argaud, Laurent, additional, Bani-Sadr, Firouzé, additional, Benezit, François, additional, Blot, Mathieu, additional, Botelho-Nevers, Elisabeth, additional, Bouadma, Lila, additional, Bouchaud, Olivier, additional, Bougon, David, additional, Bouiller, Kevin, additional, Bounes-Vardon, Fanny, additional, Boutoille, David, additional, Boyer, Alexandre, additional, Bruel, Cédric, additional, Cabié, André, additional, Canet, Emmanuel, additional, Cazanave, Charles, additional, Chabartier, Cyrille, additional, Chirouze, Catherine, additional, Clere-Jehl, Raphaël, additional, Courjon, Johan, additional, Crockett, Flora, additional, Danion, François, additional, Delbove, Agathe, additional, Dellamonica, Jean, additional, Djossou, Félix, additional, Dubost, Clément, additional, Duvignaud, Alexandre, additional, Epaulard, Olivier, additional, Epelboin, Loïc, additional, Fartoukh, Murielle, additional, Faure, Karine, additional, Faure, Emmanuel, additional, Ferry, Tristan, additional, Ficko, Cécile, additional, Figueiredo, Samy, additional, Gaborit, Benjamin, additional, Gaci, Rostane, additional, Gagneux-Brunon, Amandine, additional, Gallien, Sébastien, additional, Garot, Denis, additional, Geri, Guillaume, additional, Gibot, Sébastien, additional, Goehringer, François, additional, Gousseff, Marie, additional, Gruson, Didier, additional, Hansmann, Yves, additional, Hinschberger, Olivier, additional, Jaureguiberry, Stéphane, additional, Jeanmichel, Vanessa, additional, Kerneis, Solen, additional, Kimmoun, Antoine, additional, Klouche, Kada, additional, Lachâtre, Marie, additional, Lacombe, Karine, additional, Laine, Fabrice, additional, Lanoix, Jean-Philippe, additional, Launay, Odile, additional, Laviolle, Bruno, additional, Le Moing, Vincent, additional, Le Pavec, Jérôme, additional, Le Tulzo, Yves, additional, Le Turnier, Paul, additional, Lebeaux, David, additional, Lefevre, Benjamin, additional, Leroy, Sylvie, additional, Lescure, François-Xavier, additional, Lessire, Henry, additional, Leveau, Benjamin, additional, Loubet, Paul, additional, Makinson, Alain, additional, Malvy, Denis, additional, Marquette, Charles-Hugo, additional, Martin-Blondel, Guillaume, additional, Martinot, Martin, additional, Mayaux, Julien, additional, Mekontso-Dessap, Armand, additional, Meziani, Ferhat, additional, Mira, Jean-Paul, additional, Molina, Jean-Michel, additional, Monnet, Xavier, additional, Mootien, Joy, additional, Mourvillier, Bruno, additional, Murris-Espin, Marlène, additional, Navellou, Jean-Christophe, additional, Nseir, Saad, additional, Oulehri, Walid, additional, Perpoint, Thomas, additional, Pialoux, Gilles, additional, Pilmis, Benoît, additional, Piriou, Vincent, additional, Piroth, Lionel, additional, Pourcher, Valérie, additional, Quenot, Jean-Pierre, additional, Raffi, François, additional, Reignier, Jean, additional, Revest, Matthieu, additional, Richard, Jean-Christophe, additional, Riu-Poulenc, Béatrice, additional, Robert, Céline, additional, Roger, Pierre-Alexandre, additional, Roger, Claire, additional, Rouveix-Nordon, Elisabeth, additional, Ruch, Yvon, additional, Saidani, Nadia, additional, Sayre, Naomi, additional, Senneville, Eric, additional, Sotto, Albert, additional, Stefan, Francois, additional, Tacquard, Charles, additional, Terzi, Nicolas, additional, Textoris, Julien, additional, Thiery, Guillaume, additional, Timsit, Jean-François, additional, Tolsma, Violaine, additional, Turmel, Jean-Marie, additional, Valour, Florent, additional, Wallet, Florent, additional, Wattecamps, Guilhem, additional, Zerbib, Yoann, additional, Berna, Marc, additional, Reuter, Jean, additional, Braz, Sandra, additional, Ferreira Ribeiro, Joao-Miguel, additional, Paiva, José-Artur, additional, Roncon-Albuquerque, Roberto, additional, Gaymard, Alexandre, additional, Lina, Bruno, additional, Tubiana, Sarah, additional, Couffin-Cadièrgues, Sandrine, additional, Esperou, Hélène, additional, Dechanet, Aline, additional, Delmas, Christelle, additional, Fougerou, Claire, additional, Mercier, Noémie, additional, Noret, Marion, additional, Saillard, Juliette, additional, and Velou, Priyanka, additional
- Published
- 2022
- Full Text
- View/download PDF
54. Vaccination against serogroup B Neisseria meningitidis: Perceptions and attitudes of parents
- Author
-
Le Ngoc Tho, Sandra, Ader, Florence, Ferry, Tristan, Floret, Daniel, Arnal, Maximilien, Fargeas, Simone, Chidiac, Christian, and Valour, Florent
- Published
- 2015
- Full Text
- View/download PDF
55. Implementation of a Centralized Pharmacovigilance System in Multi-Country European Clinical Trials: Points to Consider for Academic Sponsors and Lessons Learnt from EU-Response and Connect4Children Consortia
- Author
-
Terzić, Vida, primary, Levoyer, Léa, additional, Figarella, Mélanie, additional, Bigagli, Elisabetta, additional, Mercier, Noémie, additional, Gastines, Lucie de, additional, Gibowski, Severine, additional, Trøseid, Marius, additional, Demotes, Jacques, additional, Olsen, Inge, additional, Hites, Maya, additional, Ader, Florence, additional, Lopez, José Arribas, additional, Mentré, France, additional, Espérou, Hélèhe, additional, Costagliola, Dominique, additional, Røttingen, John-Arne, additional, Poissy, Julien, additional, Rozé, Jean-Christophe, additional, Warris, Adilia, additional, O'Leary, Jackie, additional, Fernandes, Ricardo, additional, Assoumou, Lambert, additional, Hankard, Régis, additional, Turner, Mark, additional, Yazdanpanah, Yazdan, additional, and Diallo, Alpha, additional
- Published
- 2022
- Full Text
- View/download PDF
56. Real-world effectiveness of oral antivirals for COVID-19
- Author
-
Burdet, Charles, primary and Ader, Florence, additional
- Published
- 2022
- Full Text
- View/download PDF
57. Opti-4TB: A protocol for a prospective cohort study evaluating the performance of new biomarkers for active tuberculosis outcome prediction
- Author
-
Bahuaud, Olivier, primary, Genestet, Charlotte, additional, Hoffmann, Jonathan, additional, Dumitrescu, Oana, additional, and Ader, Florence, additional
- Published
- 2022
- Full Text
- View/download PDF
58. Immunocompromised patients have been neglected in COVID-19 trials: a call for action
- Author
-
Trøseid, Marius, primary, Hentzien, Maxime, additional, Ader, Florence, additional, Cardoso, Sandra Wagner, additional, Arribas, Jose R., additional, Molina, Jean-Michel, additional, Mueller, Nicolas, additional, Hites, Maya, additional, Bonnet, Fabrice, additional, Manuel, Oriol, additional, Costagliola, Dominique, additional, Grinsztejn, Beatriz, additional, Olsen, Inge Christoffer, additional, Yazdapanah, Yazdan, additional, and Calmy, Alexandra, additional
- Published
- 2022
- Full Text
- View/download PDF
59. An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
- Author
-
Ader, Florence, primary
- Published
- 2022
- Full Text
- View/download PDF
60. P397 Influence of underlying conditions on disease presentation and diagnostic strategy during pulmonary mucormycosis: Anational study of 114 cases
- Author
-
Coste, Anne, primary, Conrad, Anne, additional, Porcher, Raphaël, additional, Poirée, Sylvain, additional, Peterlin, Pierre, additional, Defrance, Claire, additional, Letscher-Bru, Valérie, additional, Morio, Florent, additional, Gastinne, Thomas, additional, Bougnoux, Marie-Elisabeth, additional, Suarez, Felipe, additional, Nevez, Gilles, additional, Dupont, Damien, additional, Ader, Florence, additional, Halfon-Domenech, Carine, additional, Ducastelle-Duprêtre, Sophie, additional, Botterel, Françoise, additional, Millon, Laurence, additional, Guillerm, Gaelle, additional, Ansart, Séverine, additional, Boutoille, David, additional, Ledoux, Marie-Pierre, additional, Robin, Christine, additional, Herbrecht, Jean-Etienne, additional, Melica, Giovanna, additional, Danion, François, additional, Paccoud, Olivier, additional, Lortholary, Olivier, additional, Herbrecht, Raoul, additional, and Lanternier, Fanny, additional
- Published
- 2022
- Full Text
- View/download PDF
61. COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency
- Author
-
Lacombe, Karine, primary, Hueso, Thomas, additional, Porcher, Raphael, additional, Mekinian, Arsène, additional, Chiarabini, Thibault, additional, Georgin-Lavialle, Sophie, additional, Ader, Florence, additional, Saison, Julien, additional, Blondel, Guillaume Martin, additional, De Castro, Nathalie, additional, Bonnet, Fabrice, additional, Cazanave, Charles, additional, François, Anne, additional, Morel, Pascal, additional, Hermine, Olivier, additional, Pourcher, Valérie, additional, Michel, Marc, additional, Lescure, Xavier, additional, Soussi, Nora, additional, Brun, Philippe, additional, Pommeret, Fanny, additional, Sellier, Pierre-Olivier, additional, Rousset, Stella, additional, Piroth, Lionel, additional, Michot, Jean-Marie, additional, Baron, Gabriel, additional, De Lamballerie, Xavier, additional, Mariette, Xavier, additional, Tharaux, Pierre-Louis, additional, Resche-Rigon, Matthieu, additional, Ravaud, Philippe, additional, Simon, Tabassome, additional, and Tiberghien, Pierre, additional
- Published
- 2022
- Full Text
- View/download PDF
62. Prognosis and factors associated with disseminated nocardiosis: a ten-year multicenter study
- Author
-
Soueges, Sarah, primary, Bouiller, Kevin, additional, Botelho-Nevers, Elisabeth, additional, Gagneux-Brunon, Amandine, additional, Chirouze, Catherine, additional, Rodriguez-Nava, Veronica, additional, Dumitrescu, Oana, additional, Triffault-Fillit, Claire, additional, Conrad, Anne, additional, Lebeaux, David, additional, Hodille, Elisabeth, additional, Valour, Florent, additional, and Ader, Florence, additional
- Published
- 2022
- Full Text
- View/download PDF
63. Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants
- Author
-
Ader, Florence, Argaud, Laurent, Aubrun, Frédéric, Fellahi, Jean-Luc, Guichon, Céline, Juillard, Laurent, Leclerc, Vincent, Miossec, Charline, Paillet, Carole, Plesa, Alexandra, Richard, Jean-Christophe, Roux, Sandrine, Wallet, Florent, Bienvenu, A.L., Pradat, P., Matusik, E., Piriou, V., Rimmelé, T., Parant, F., Tod, M., Leboucher, G., and Goutelle, S.
- Published
- 2023
- Full Text
- View/download PDF
64. A Simple-to-Perform ifn-γ mRNA Gene Expression Assay on Whole Blood Accurately Appraises Varicella Zoster Virus-Specific Cell-Mediated Immunity After Allogeneic Hematopoietic Stem Cell Transplantation
- Author
-
Boccard, Mathilde, primary, Conrad, Anne, additional, Mouton, William, additional, Valour, Florent, additional, Roure-Sobas, Chantal, additional, Frobert, Emilie, additional, Rohmer, Barbara, additional, Alcazer, Vincent, additional, Labussière-Wallet, Hélène, additional, Ghesquières, Hervé, additional, Venet, Fabienne, additional, Brengel-Pesce, Karen, additional, Trouillet-Assant, Sophie, additional, and Ader, Florence, additional
- Published
- 2022
- Full Text
- View/download PDF
65. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose
- Author
-
Luque-Paz, David, primary, Sesques, Pierre, additional, Wallet, Florent, additional, Bachy, Emmanuel, additional, and Ader, Florence, additional
- Published
- 2022
- Full Text
- View/download PDF
66. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study
- Author
-
Paret, Raphael, primary, Le Bourgeois, Amandine, additional, Guillerm, Gaëlle, additional, Tessoulin, Benoit, additional, Rezig, Schéhérazade, additional, Gastinne, Thomas, additional, Couturier, Marie Anne, additional, Boutoille, David, additional, Lecomte, Raphael, additional, Ader, Florence, additional, Le Gouill, Steven, additional, Ansart, Séverine, additional, Talarmin, Jean Philippe, additional, and Gaborit, Benjamin, additional
- Published
- 2022
- Full Text
- View/download PDF
67. Prise en charge thérapeutique des tuberculoses résistantes
- Author
-
Revest, Matthieu, primary, Veziris, Nicolas, additional, Guthmann, Jean-Paul, additional, Gugliemetti, Lorenzo, additional, Ader, Florence, additional, Rioux, Christophe, additional, Pourcher, Valérie, additional, Aubry, Alexandra, additional, and Robert, Jérôme, additional
- Published
- 2022
- Full Text
- View/download PDF
68. Mycobacterium tuberculosis genetic features associated with pulmonary tuberculosis severity
- Author
-
Genestet, Charlotte, primary, Refregier, Guislaine, additional, Hodille, Elisabeth, additional, Zein-Eddine, Rima, additional, Le Meur, Adrien, additional, Hak, Fiona, additional, Barbry, Alexia, additional, Westeel, Emilie, additional, Berland, Jean-Luc, additional, Engelmann, Astrid, additional, Verdier, Isabelle, additional, Lina, Gerard, additional, Ader, Florence, additional, Dray, Stephane, additional, Jacob, Laurent, additional, Massol, Francois, additional, Venner, Samuel, additional, and Dumitrescu, Oana, additional
- Published
- 2022
- Full Text
- View/download PDF
69. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients
- Author
-
Valour, Florent, Cotte, Laurent, Voirin, Nicolas, Godinot, Matthieu, Ader, Florence, Ferry, Tristan, Vanhems, Philippe, and Chidiac, Christian
- Published
- 2014
- Full Text
- View/download PDF
70. Smoking‐associated morbidities on computed tomography lung cancer screens in HIV‐infected smokers
- Author
-
Bommart, S, Cournil, A, Eymard‐Duvernay, S, Raffi, F, Bouassida, I, Le Moing, V, Reynes, J, Makinson, A, Yazdanpanah, Yazdan, Cheret, Antoine, Ajana, Faïza, Alcaraz, Isabelle, Baclet, Véronique, Melliez, Hugues, Valette, Michel, Viget, Nathalie, De La Tribonniere, Xavier, Huleux, Thomas, Séverine, Séverine Bonne, Biekre, Raphaël, Pasquet, Armelle, Allienne, Christophe, Behra, Jean Marie, Meybeck, Agnès, Aissi, Emmanuelle, Abgrall, Sophie, Bouchaud, Olivier, Barruet, Régine, Rouges, François, Kandel, Tania, Mechai, Fréderic, Brillet, Pierre‐Yves, Brauner, Michel, Dellamonica, Pierre, De Salvador, Francine, Cua, Eric, Leplatois, Anne, Naqvi, Alissa, Durant, Jacques, Ceppi, Carole, Sanderson, Frédéric, Rosenthal, Eric, Chassang, Madleen, Chevallier, Patrick, Dunais, Brigitte, Tattevin, Pierre, Lena, Hervé, Lentz, Pierre‐Axel, Michelet, Christian, Arvieux, Cédric, Revest, Mathieu, Soula, Faouzi, Chapplain, Jean‐Marc, Leroy, Hélène, Meunier, Catherine, Poizot‐Martin, Isabelle, Faucher, Olivia, Menard, Amélie, Bregigeon, Sylvie, de Lamarliere, Perrine Geneau, Champsaur, Pierre, Durieux, Olivier, Cloarec, Nicolas, Allavena, Clotilde, Feuillebois, Nicolas, Mounoury, Olivier, Bouchez, Sabelline, Billaud, Eric, Reliquet, Véronique, Bonnet, Bénédicte, Brunet, Cécile, Point, Patrick, Boutoille, David, Le Houssine, Pascale Morineau, Delemazure, Anne Sophie, Duvivier, Claudine, Catherinot, Emilie, Tehrani, Michka Shoai, Poiree, Sylvain, Zucman, David, Majerholc, Catherine, Couderc, Louis‐Jean, Mellot, François, Sherrer, Antoine, Ferry, Tristan, Koffi, Joseph, Boibieux, André, Miailhes, Patrick, Cotte, Laurent, Perpoint, Thomas, Lippman, Joanna, Norman, Claude Augustin, biron, Francois, Senechar, Agathe, Ader, Florence, Pialloux, Gilles, LʼYavanc, Thomas, Slama, Laurence, Chas, Julie, Le Nagat, Sophie, Khalil, Antoine, Carette, Marie France, Bonnet, Fabrice, Morlat, Philippe, Lacoste, Denis, Vandenhende, Marie, Receveur, Marie Catherine, Paccalin, Francois, Caldato, Sabrina, Bernard, Noëlle, Hessemfar, Mojgan, Pistone, Thierry, Malvy, Denis, Thibaut, Pierre, Pertusa, Marie Carmen, Cornelou, Olivier, Laurent, Francois, Mercie, Patrick, Faure, Isabelle, Dondia, Denis, Martell, Cedric, Duffau, Pierre, Mauboussin, Jean Marc, Barbuat, Claudine, Rouanet, Isabelle, Metge, Liliane, Jacquet, Jean‐Marc, Atoui, Nadine, Loriette, Mickael, Morquin, David, Fauchere, Vincent, Favier, Carine, Merle, Corinne, Baillat, Vincent, Silva, Antoine Da, Mansouri, Rachid, Kovacsik‐Vernhet, Hélène, Pujol, Jean‐Louis, Quantin, Xavier, and Hayot, Maurice
- Published
- 2017
- Full Text
- View/download PDF
71. Clinical Presentation, Diagnosis, and Bacterial Epidemiology of Peritoneal Tuberculosis in Two University Hospitals in France
- Author
-
Cavalli, Zoé, Ader, Florence, Valour, Florent, Saison, Julien, Boussel, Loïc, Dumitrescu, Oana, Perpoint, Thomas, Chidiac, Christian, May, Thierry, Ferry, Tristan, Adelaïde, L., Ader, F., Biron, F., Boibieux, A., Bouaziz, A., Bouledrak, K., Braun, E., Broussolle, C., Carret, G., Catho, G., Charhon, N., Chidiac, C., Chumbi-Flores, W., Coppere, B., Couraud, S., Demontclos, M., Devouassoux, G., Dumitrescu, O., Ernesto, S., Ferry, T., Floret, D., Fredenucci, I., Freymond, N., Gardes, S., Gerbier-Colomban, S., Gillet, Y., Girard-Madoux, M. H., Goutelle, S., Grando, J., Grima, R., Hees, L., Hodille, E., Hot, A., Karsenty, J., Kiakouama-Maleka, L., Lina, G., Maury, J. M., Miailhes, P., Moreau, L., Nesme, P., Ninet, J., Perard, L., Perpoint, T., Perrot, E., Ranc, A. G., Rasigade, J. P., Reix, R., Renaud-Baron, A. S., Saison, J., Senechal, A., Sève, P., Souquet, P. J., van Thai, H., Tronc, F., Valour, F., Vanhems, P., and Lyon TB Study group
- Published
- 2016
- Full Text
- View/download PDF
72. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial
- Author
-
Ader, Florence, primary, Bouscambert-Duchamp, Maude, additional, Hites, Maya, additional, Peiffer-Smadja, Nathan, additional, Poissy, Julien, additional, Belhadi, Drifa, additional, Diallo, Alpha, additional, Delmas, Christelle, additional, Saillard, Juliette, additional, Dechanet, Aline, additional, Fougerou, Claire, additional, Lê, Minh-Patrick, additional, Peytavin, Gilles, additional, Mercier, Noémie, additional, Velou, Priyanka, additional, Tubiana, Sarah, additional, Lescure, Xavier, additional, Faure, Emmanuel, additional, Nseir, Saad, additional, Richard, Jean-Christophe, additional, Wallet, Florent, additional, Goehringer, François, additional, Lefèvre, Benjamin, additional, Kimmoun, Antoine, additional, Raffi, François, additional, Gaborit, Benjamin, additional, Reignier, Jean, additional, Lanoix, Jean-Philippe, additional, Andrejak, Claire, additional, Zerbib, Yoann, additional, Bani-Sadr, Firouzé, additional, Mourvilliers, Bruno, additional, Danion, François, additional, Ruch, Yvon, additional, Clere-Jehl, Raphaël, additional, Le Moing, Vincent, additional, Klouche, Kada, additional, Lacombe, Karine, additional, Martin-Blondel, Guillaume, additional, Vardon-Bounes, Fanny, additional, Cabié, André, additional, Turmel, Jean-Marie, additional, Piroth, Lionel, additional, Blot, Mathieu, additional, Botelho-Nevers, Élisabeth, additional, Gagneux-Brunon, Amandine, additional, Thiery, Guillaume, additional, Bénézit, François, additional, Gaci, Rostane, additional, Mootien, Joy, additional, Gallien, Sébastien, additional, Garot, Denis, additional, Bouiller, Kevin, additional, Epelboin, Loïc, additional, Jauréguiberry, Stéphane, additional, Gaymard, Alexandre, additional, Verschelden, Gil, additional, Braz, Sandra, additional, Ferreira Ribeiro, Joao Miguel, additional, Joannidis, Michael, additional, Staub, Thérèse, additional, Altdorfer, Antoine, additional, Greil, Richard, additional, Egle, Alexander, additional, Guedj, Jérémie, additional, Noret, Marion, additional, Roncon-Albuquerque, Roberto, additional, Paiva, Jose-Artur, additional, Lina, Bruno, additional, Costagliola, Dominique, additional, Yazdanpanah, Yazdan, additional, Burdet, Charles, additional, and Mentré, France, additional
- Published
- 2022
- Full Text
- View/download PDF
73. In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion
- Author
-
Chedid, Carole, primary, Andrieu, Thibault, additional, Kokhreidze, Eka, additional, Tukvadze, Nestani, additional, Biswas, Samanta, additional, Ather, Md. Fahim, additional, Uddin, Mohammad Khaja Mafij, additional, Banu, Sayera, additional, De Maio, Flavio, additional, Delogu, Giovanni, additional, Endtz, Hubert, additional, Goletti, Delia, additional, Vocanson, Marc, additional, Dumitrescu, Oana, additional, Hoffmann, Jonathan, additional, and Ader, Florence, additional
- Published
- 2022
- Full Text
- View/download PDF
74. Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
- Author
-
Daull, Anne-Marie, primary, Dubois, Valérie, additional, Labussière-Wallet, Hélène, additional, Venet, Fabienne, additional, Barraco, Fiorenza, additional, Ducastelle-Lepretre, Sophie, additional, Larcher, Marie-Virginie, additional, Balsat, Marie, additional, Gilis, Lila, additional, Fossard, Gaëlle, additional, Ghesquières, Hervé, additional, Heiblig, Maël, additional, Ader, Florence, additional, and Alcazer, Vincent, additional
- Published
- 2022
- Full Text
- View/download PDF
75. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial
- Author
-
Lingas, Guillaume, primary, Néant, Nadège, additional, Gaymard, Alexandre, additional, Belhadi, Drifa, additional, Peytavin, Gilles, additional, Hites, Maya, additional, Staub, Thérèse, additional, Greil, Richard, additional, Paiva, Jose-Artur, additional, Poissy, Julien, additional, Peiffer-Smadja, Nathan, additional, Costagliola, Dominique, additional, Yazdanpanah, Yazdan, additional, Wallet, Florent, additional, Gagneux-Brunon, Amandine, additional, Mentré, France, additional, Ader, Florence, additional, Burdet, Charles, additional, Guedj, Jérémie, additional, and Bouscambert-Duchamp, Maude, additional
- Published
- 2022
- Full Text
- View/download PDF
76. Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients
- Author
-
Sesques, Pierre, primary, Bachy, Emmanuel, additional, Ferrant, Emmanuelle, additional, Safar, Violaine, additional, Gossez, Morgane, additional, Morfin-Sherpa, Florence, additional, Venet, Fabienne, additional, and Ader, Florence, additional
- Published
- 2022
- Full Text
- View/download PDF
77. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial
- Author
-
Ader, Florence, primary, Peiffer-Smadja, Nathan, additional, Poissy, Julien, additional, Bouscambert-Duchamp, Maude, additional, Belhadi, Drifa, additional, Diallo, Alpha, additional, Delmas, Christelle, additional, Saillard, Juliette, additional, Dechanet, Aline, additional, Mercier, Noémie, additional, Dupont, Axelle, additional, Alfaiate, Toni, additional, Lescure, François-Xavier, additional, Raffi, François, additional, Goehringer, François, additional, Kimmoun, Antoine, additional, Jaureguiberry, Stéphane, additional, Reignier, Jean, additional, Nseir, Saad, additional, Danion, François, additional, Clere-Jehl, Raphael, additional, Bouiller, Kévin, additional, Navellou, Jean-Christophe, additional, Tolsma, Violaine, additional, Cabie, André, additional, Dubost, Clément, additional, Courjon, Johan, additional, Leroy, Sylvie, additional, Mootien, Joy, additional, Gaci, Rostane, additional, Mourvillier, Bruno, additional, Faure, Emmanuel, additional, Pourcher, Valérie, additional, Gallien, Sébastien, additional, Launay, Odile, additional, Lacombe, Karine, additional, Lanoix, Jean-Philippe, additional, Makinson, Alain, additional, Martin-Blondel, Guillaume, additional, Bouadma, Lila, additional, Botelho-Nevers, Elisabeth, additional, Gagneux-Brunon, Amandine, additional, Epaulard, Olivier, additional, Piroth, Lionel, additional, Wallet, Florent, additional, Richard, Jean-Christophe, additional, Reuter, Jean, additional, Staub, Thérèse, additional, Lina, Bruno, additional, Noret, Marion, additional, Andrejak, Claire, additional, Lê, Minh Patrick, additional, Peytavin, Gilles, additional, Hites, Maya, additional, Costagliola, Dominique, additional, Yazdanpanah, Yazdan, additional, Burdet, Charles, additional, and Mentre, France, additional
- Published
- 2022
- Full Text
- View/download PDF
78. Disappearance of FDG uptake on PET scan after antimicrobial therapy could help for the diagnosis of Coxiella burnetii spondylodiscitis
- Author
-
Gaudé, Marine, Julien, Saison, Laurent, Frédéric, Ferry, Tristan, Perpoint, Thomas, Boibieux, André, Biron, François, Ader, Florence, Valour, Florent, Roux, Sandrine, Daoud, Fatiha, Lippman, Johanna, Braun, Evelyne, Vallat, Marie-Paule, Miailhes, Patrick, Chidiac, Christian, Gillet, Yves, Hees, Laure, Lustig, Sébastien, Neyret, Philippe, Reynaud, Olivier, Peltier, Adrien, Viste, Anthony, Bérard, Jean-Baptiste, Dalat, Frédéric, Cantin, Olivier, Desmarchelier, Romain, Vermersch, Thibault, Fessy, Michel-Henry, Barrey, Cédric, Signorelli, Francesco, Jouanneau, Emmanuel, Jacquesson, Timothée, Mojallal, Ali, Boucher, Fabien, Shipkov, Hristo, Ismail, Mehdi, Chateau, Joseph, Vandenesch, François, Rasigade, Jean-Philippe, Dupieux, Céline, Trouillet-Assant, Sophie, Morelec, Isabelle, Janier, Marc, Giammarile, Francesco, Tod, Michel, Gagnieu, Marie-Claude, Goutelle, Sylvain, and Mabrut, Eugénie
- Published
- 2016
- Full Text
- View/download PDF
79. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results
- Author
-
Pan, Hongchao, Peto, Richard, Henao-Restrepo, Ana-Maria, Preziosi, Marie-Pierre, Sathiyamoorthy, Vasee, Abdool Karim, Quarraisha, Alejandria, Marissa M, Hernández García, César, Kieny, Marie-Paule, Malekzadeh, Reza, Murthy, Srinivas, Reddy, K Srinath, Roses Periago, Mirta, Abi Hanna, Pierre, Abutidze, Akaki, Ader, Florence, Al-Bader, Abdullah M, Alhasawi, Almonther, Allum, Emma, Al Mawali, Adhra, Alotaibi, Athari, Alvarez-Moreno, Carlos A, Appadoo, Sheila, Arts, Derk, Asiri, Abdullah, Aukrust, Pål, Barratt-Due, Andreas, Bayih, Abebe Genetu, Beaumont, Helena, Bellani, Samir, Benassi, Virginia, Bhargava, Balram, Branca, Mattia, Cappel-Porter, Heike B C, Cerrato, Nery, Cheick Haidara, Fadima, Chow, Ting S, Como, Najada, Eustace, Joe, Gabunia, Tamar, García, Patricia J, Godbole, Sheela, Gotuzzo, Eduardo, Griskevicius, Laimonas, Hamra, Rasha, Hassan, Mariam, Hassany, Mohamed, Hutton, David, Irmansyah, Irmansyah, Jancoriene, Ligita, Khamis, Faryal, Kirwan, Jana, Kumar, Suresh, Lopardo, Gustavo, Lydon, Patrick, Magrini, Nicola, Manevska, Suzana, Manuel, Oriol, McGinty, Sibylle, Medina, Marco T, Mesa Rubio, María L, Miranda-Montoya, Maria C, Nel, Jeremy, Nunes, Estevao P, Perola, Markus, Portolés, Antonio, Rasmin, Menaldi, Raza, Aun, Rees, Helen, Reges, Paula, Rogers, Chris, Salami, Kolawole, Salvadori, Marina, Sauermann, Mamatha, Sinani, Narvina, Sow, Samba, Sterne, Jonathan A C, Stevanovikj, Milena, Tacconelli, Evelina, Tavares Maltez, Fernando Manuel, Teferi, Mekonnen, Tikkinen, Kari, Trelle, Sven, Tsertsvadze, Tengiz, Zaid, Hala, Rottingen, Arne, Swaminathan, Soumya, and Ryan, Michael
- Abstract
BACKGROUND World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19). METHODS We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry. RESULTS At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P = 0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P = 0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P = 0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration. CONCLUSIONS These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.).
- Published
- 2022
- Full Text
- View/download PDF
80. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group
- Author
-
Diallo, Alpha Troseid, Marius Simensen, Victoria Charlotte and Boston, Anais Demotes, Jacques Olsen, Inge Christoffer and Chung, Florence Paiva, Jose Artur Hites, Maya Ader, Florence and Arribas, Jose Ramon Baratt-Due, Andreas Melien, Oyvind and Tacconelli, Evelina Staub, Therese Greil, Richard Tsiodras, Sotirios Briel, Matthias Esperou, Helene Mentre, France and Eustace, Joe Saillard, Juliette Delmas, Christelle LeMestre, Soizic Dumousseaux, Marina Costagliola, Dominique Rottingen, John-Arne Yazdanpanah, Yazdan EU-Response Investigators Grp
- Published
- 2022
81. Outcome of Progressive Multifocal Leukoencephalopathy Treated by Interleukin-7
- Author
-
Lajaunie, Rébecca, Mainardi, Ilaria, Gasnault, Jacques, Rousseau, Vanessa, Tarantino, Andrea, Sommet, Agnès, Cinque, Paola, Martin-Blondel, Guillaume, Debard, Alexa, Delobel, Pierre, Pansu, Nathalie, Gollion, Cédric, Benaiteau, Marie, Jacomet, Christine, Mélé, Nicolas, Moulignier, Antoine, Suarez, Felipe, Ruch, Yvon, Tranchant, Christine, Lemaignen, Adrien, Langner-Lemercier, Sophie, Buzele, Rodolphe, Guffroy, Aurelien, Moluçon-Chabrot, Cécile, Tattevin, Pierre, Melica, Giovanna, Badiu, Carmen‐ionela, Cheraud-Bonfort, Chrystel, Salmon, Anne, Alstadhaug, Karl Bjornar, Kuhlmann, F. Matthew, Gorza, Lucas, Wang, Adrien, Wille, Heidi, Curlier, Elodie, Hessamfar, Mojgan, Valour, Florent, Perpoint, Thomas, Koralnik, Igor, Decaestecker, Kevin, Vindrios, William, Guilbert, Anne, Boulesteix, Jean Marc, Verdière, Sylvie Colin De, Roux, Antoine, Patel, Amila, Fabian, Michelle, Harel, Asaff, Wyplosz, Benjamin, Ader, Florence, Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), San Raffaele Scientific Institute, Vita-Salute San Raffaele University and Center for Translational Genomics and Bioinformatics, Immunologie intégrative des tumeurs (UMR 1186), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and This study was not funded.
- Subjects
MESH: Humans ,Interleukin-7 ,MESH: Leukoencephalopathy, Progressive Multifocal ,MESH: JC Virus ,Leukoencephalopathy, Progressive Multifocal ,MESH: Retrospective Studies ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,HIV Infections ,MESH: HIV Infections ,JC Virus ,MESH: Interleukin-7 ,Neurology ,Hematologic Neoplasms ,Humans ,Neurology (clinical) ,MESH: Hematologic Neoplasms ,Retrospective Studies - Abstract
International audience; Objective: Restoring anti-JC virus (JCV) immunity is the only treatment of progressive multifocal leukoencephalopathy (PML). Interleukin-7 is a cytokine that increases number and function of T cells. We analyzed a population of PML patients who received recombinant human IL-7 (rhIL-7) to estimate survival and its determinants.Methods: After exclusion of patients with missing data or receiving other immunotherapies, findings from 64 patients with proven PML who received rhIL-7 between 2007 and 2020 were retrospectively analyzed. Logistic regression was used to analyze variables associated with one-year survival.Results: Underlying conditions were HIV/AIDS (n = 27, 42%), hematological malignancies (n = 16, 25%), primary immunodeficiencies (n = 13, 20%), solid organ transplantation (n = 4, 6%) and chronic inflammatory diseases (n = 4, 6%). One-year survival was 54.7% and did not differ by underlying condition. Survival was not associated with baseline characteristics, but with a >50% increase in blood lymphocytes (OR 4.1, 95%CI 1.2-14.9) and CD4+ T cells (OR 5.9, 95%CI 1.7-23.3), and a > 1 log copies/mL decrease in cerebrospinal fluid JCV DNA (OR 7.6, 95%CI 1.6-56.1) during the first month after rhIL-7 initiation. Side effects were mainly local and flu-like symptoms (n = 8, 12.5%) and PML-immune reconstitution inflammatory syndrome (IRIS) (n = 5, 8%).Interpretation: In this non-controlled retrospective study, survival did not differ from that expected in HIV/AIDS patients, but might have been improved in those with hematological malignancies, primary immunodeficiencies and transplant recipients. RhIL-7 might have contributed to the increase in blood lymphocytes and decrease in CSF JCV replication that were associated with better survival. ANN NEUROL 2022;91:496-505.
- Published
- 2021
82. Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis.
- Author
-
Bienvenu, Anne-Lise, Bestion, Audrey, Pradat, Pierre, Richard, Jean-Christophe, Argaud, Laurent, Guichon, Céline, Roux, Sandrine, Piriou, Vincent, Paillet, Carole, Leboucher, Gilles, the Antifungal study group, Ader, Florence, Aubrun, Frédéric, Besson, Charlotte, Bréant, Valentine, Doudet, Charlotte, Ducastelle-Leprêtre, Sophie, Dupont, Damien, Guillemin, Marie-Delphine, and Leray, Véronique
- Abstract
Background: In the context of COVID-19 pandemic, antifungal overuse may have occurred in our hospitals as it has been previously reported for antibacterials. Methods: To investigate the impact of COVID-19 on antifungal consumption, a multicenter retrospective study including four medical sites and 14 intensive care units (ICU) was performed. Antifungal consumption and incidences of invasive fungal diseases before and during COVID-19 pandemic, for non-COVID-19 patients and COVID-19 patients, were described. Results: An increase in voriconazole consumption was observed in 2020 compared with 2019 for both the whole hospital and the ICU (+ 40.3% and + 63.7%, respectively), whereas the incidence of invasive aspergillosis significantly increased in slightly lower proportions in the ICU (+ 46%). Caspofungin consumption also increased in 2020 compared to 2019 for both the whole hospital and the ICU (+ 34.9% and + 17.0%, respectively) with an increased incidence of invasive candidiasis in the whole hospital and the ICU but in lower proportions (+ 20.0% and + 10.9%, respectively). Conclusions: We observed an increased consumption of antifungals including voriconazole and caspofungin in our hospital during the COVID-19 pandemic and explained in part by an increased incidence of invasive fungal diseases in COVID-19 patients. These results are of utmost importance as it raises concern about the urgent need for appropriate antifungal stewardship activities to control antifungal consumption. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
83. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group
- Author
-
Diallo, Alpha, Trøseid, Marius, Simensen, Victoria Charlotte, Boston, Anaïs, Demotes, Jacques, Olsen, Inge Christoffer, Chung, Florence, Paiva, José Artur, Hites, Maya, Ader, Florence, Arribas, Jose Ramon, Baratt-Due, Andreas, Melien, Øyvind, Tacconelli, Evelina, Staub, Thèrèse, Greil, Richard, Tsiodras, Sotirios, Briel, Matthias, Esperou, Hélène, Mentré, France, Eustace, Joe, Saillard, Juliette, Delmas, Christelle, LeMestre, Soizic, Dumousseaux, Marina, Costagliola, Dominique, Røttingen, John-Arne, and Yazdanpanah, Yazdan
- Published
- 2022
- Full Text
- View/download PDF
84. Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial
- Author
-
Millon, Laurence, primary, Caillot, Denis, additional, Berceanu, Ana, additional, Bretagne, Stéphane, additional, Lanternier, Fanny, additional, Morio, Florent, additional, Letscher-Bru, Valérie, additional, Dalle, Frédéric, additional, Denis, Blandine, additional, Alanio, Alexandre, additional, Boutoille, David, additional, Bougnoux, Marie Elisabeth, additional, Botterel, Françoise, additional, Chouaki, Taieb, additional, Charbonnier, Amandine, additional, Ader, Florence, additional, Dupont, Damien, additional, Bellanger, Anne Pauline, additional, Rocchi, Steffi, additional, Scherer, Emeline, additional, Gbaguidi-Haore, Houssein, additional, and Herbrecht, Raoul, additional
- Published
- 2022
- Full Text
- View/download PDF
85. Implementation of a complex bone and joint infection phage therapy centre in France: lessons to be learned after 4 years' experience
- Author
-
Ferry, Tristan, primary, Kolenda, Camille, additional, Briot, Thomas, additional, Lustig, Sébastien, additional, Leboucher, Gilles, additional, Laurent, Frédéric, additional, Ferry, Tristan, additional, Valour, Florent, additional, Perpoint, Thomas, additional, Ader, Florence, additional, Roux, Sandrine, additional, Becker, Agathe, additional, Triffault-Fillit, Claire, additional, Conrad, Anne, additional, Pouderoux, Cécile, additional, Chauvelot, Pierre, additional, Chabert, Paul, additional, Lippman, Johanna, additional, Braun, Evelyne, additional, Servien, Elvire, additional, Batailler, Cécile, additional, Gunst, Stanislas, additional, Schmidt, Axel, additional, Sappey-Marinier, Eliott, additional, Ode, Quentin, additional, Fessy, Michel-Henry, additional, Viste, Anthony, additional, Besse, Jean-Luc, additional, Chaudier, Philippe, additional, Louboutin, Lucie, additional, Van Haecke, Adrien, additional, Mercier, Marcelle, additional, Belgaid, Vincent, additional, Gazarian, Aram, additional, Walch, Arnaud, additional, Bertani, Antoine, additional, Rongieras, Frédéric, additional, Martres, Sébastien, additional, Trouillet, Franck, additional, Barrey, Cédric, additional, Mojallal, Ali, additional, Brosset, Sophie, additional, Hanriat, Camille, additional, Person, Hélène, additional, Céruse, Philippe, additional, Fuchsmann, Carine, additional, Gleizal, Arnaud, additional, Aubrun, Frédéric, additional, Dziadzko, Mikhail, additional, Macabéo, Caroline, additional, Patrascu, Dana, additional, Beraud, Laetitia, additional, Roussel-Gaillard, Tiphaine, additional, Dupieux, Céline, additional, Josse, Jérôme, additional, Craighero, Fabien, additional, Boussel, Loic, additional, Pialat, Jean-Baptiste, additional, Morelec, Isabelle, additional, Tod, Michel, additional, Gagnieu, Marie-Claude, additional, Goutelle, Sylvain, additional, Mabrut, Eugénie, additional, Medina, Mathieu, additional, Laumay, Floriane, additional, Bonhomme, Melanie, additional, Blazere, Leslie, additional, Legendre, Tiphaine, additional, Terrazzoni, Eline, additional, Pirot, Fabrice, additional, Merienne, Camille, additional, Filali, Samira, additional, and Lapras, Benjamine, additional
- Published
- 2022
- Full Text
- View/download PDF
86. Effects of Remdesivir in Hospitalized Patients with COVID-19: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials
- Author
-
Amstutz, Alain, primary, Speich, Benjamin, additional, Mentré, France, additional, Rueegg, Corina Silvia, additional, Belhadi, Drifa, additional, Assoumou, Lambert, additional, Burdet, Charles, additional, Murthy, Srinivas, additional, Dodd, Lori Elizabeth, additional, Wang, Yeming, additional, Tikkinen, Kari, additional, Ader, Florence, additional, Hites, Maya, additional, Bouscambert-Duchamp, Maude, additional, Trabaud, Mary-Anne, additional, Fralick, Mike, additional, Lee, Todd Campbell, additional, Pinto, Ruxandra, additional, Barratt-Due, Andreas, additional, Lund-Johansen, Fridtjof, additional, Müller, Fredrik, additional, Nevalainen, Olli, additional, Cao, Bin, additional, Bonnett, Tyler, additional, Griessbach, Alexandra, additional, Taji Heravi, Ala, additional, Schönenberger, Christof, additional, Janiaud, Perrine, additional, Werlen, Laura, additional, Aghlmandi, Soheila, additional, Schandelmaier, Stefan, additional, Yazdanpanah, Yazdan, additional, Costagliola, Dominique, additional, Olsen, Inge Christoffer, additional, and Briel, Matthias, additional
- Published
- 2022
- Full Text
- View/download PDF
87. Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial
- Author
-
Trøseid, Marius, primary, Arribas, JR, additional, Assoumou, Lambert, additional, Holten, Aleksander Rygh, additional, Poissy, Julien, additional, Terzić, Vida, additional, Mazzaferri, Fulvia, additional, Rodríguez-Baño, Jesús , additional, Eustace, Joe, additional, Hites, Maya, additional, Joannidis, Michael, additional, Paiva, Jose-Artur, additional, Reuter, Jean, additional, Püntmann, Isabel, additional, Patrick-Brown, Thale, additional, Westerheim, Elin, additional, Nezvalova-Henriksen, Katerina, additional, Beniguel, Lydie, additional, Dahl, Tuva Børresdatter, additional, Bouscambert-Duchamp, Maude, additional, Halanova, Monika, additional, Peterfi, Zoltan, additional, Tsiodras, Sotirios, additional, Rezek, Michael, additional, Briel, Matthias, additional, Unal, Serhat, additional, Schlegel, Martin, additional, Ader, Florence, additional, Lacombe, Karine, additional, Amdal, Cecilie Delphin, additional, Serge Rodrigues, Serge Rodrigues, additional, Tonby, Kristian, additional, Gaudet, Alexandre, additional, Heggelund, Lars, additional, Mootien, Joy, additional, Johannessen, Asgeir, additional, Møller, Jannicke Horjen, additional, Diaz Pollan, Beatriz, additional, Tveita, Anders, additional, Kildal, Anders Benjamin, additional, Richard, Jean-Christophe, additional, Dalgard, Olav, additional, Simensen, Victoria Charlotte, additional, Baldé, Aliou, additional, de Gastines, Lucie, additional, del Álamo, Marta, additional, Aydin, Burç, additional, Lund-Johansen, Fridtjof, additional, Trabaud, Mary-Anne, additional, Diallo, Alpha, additional, Halvorsen, Bente, additional, Røttingen, John-Arne, additional, Tacconelli, Evelina, additional, Yadanapanah, Yazdan, additional, Olsen, Inge Christoffer, additional, and Costagliola, Dominique, additional
- Published
- 2022
- Full Text
- View/download PDF
88. Assessing the evidence on remdesivir
- Author
-
Trøseid, Marius, primary, Hites, Maya, additional, Barratt-Due, Andreas, additional, Ader, Florence, additional, and Yazdanpanah, Yazdan, additional
- Published
- 2021
- Full Text
- View/download PDF
89. Reactivation of Clostridium tertium bone infection 30 years after the Iran–Iraq war
- Author
-
Virot, Emilie, Servien, Elvire, Laurent, Frederic, Ferry, Tristan, Perpoint, Thomas, Boibieux, André, Biron, François, Ader, Florence, Saison, Julien, Valour, Florent, Daoud, Fatiha, Lippman, Johanna, Braun, Evelyne, Vallat, Marie-Paule, Miailhes, Patrick, Chidiac, Christian, Peyramond, Dominique, Lustig, Sébastien, Neyret, Philippe, Reynaud, Olivier, Debette, Caroline, Peltier, Adrien, Viste, Anthony, Bérard, Jean-Baptiste, Dalat, Frédéric, Cantin, Olivier, Desmarchelier, Romain, Fessy, Michel-Henry, Barrey, Cédric, Signorelli, Francesco, Jouanneau, Emmanuel, Jacquesson, Timothée, Breton, Pierre, Mojallal, Ali, Boucher, Fabien, Shipkov, Hristo, Vandenesch, François, Rasigade, Jean-Philippe, Dupieux, Céline, Boussel, Loïc, Pialat, Jean-Baptiste, Morelec, Isabelle, Janier, Marc, Giammarile, Francesco, Tod, Michel, Gagnieu, Marie-Claude, Goutelle, Sylvain, and Mabrut, Eugénie
- Published
- 2015
- Full Text
- View/download PDF
90. A 22-year-old woman with right lumpy jaw syndrome and fistula
- Author
-
Valour, F, Chidiac, C, Ferry, T, Ferry, Tristan, Perpoint, Thomas, Boibieux, André, Biron, François, Ader, Florence, Saison, Julien, Valour, Florent, Daoud, Fatiha, Lippman, Johanna, Braun, Evelyne, Vallat, Marie-Paule, Miailhes, Patrick, Chidiac, Christian, Peyramond, Dominique, Lustig, Sébastien, Neyret, Philippe, Reynaud, Olivier, Debette, Caroline, Peltier, Adrien, Viste, Anthony, Bérard, Jean-Baptiste, Dalat, Frédéric, Cantin, Olivier, Desmarchelier, Romain, Vermersch, Thibault, Fessy, Michel-Henry, Barrey, Cédric, Signorelli, Francesco, Jouanneau, Emmanuel, Jacquesson, Timothée, Breton, Pierre, Mojallal, Ali, Boucher, Fabien, Shipkov, Hristo, Laurent, Frederic, Vandenesch, François, Rasigade, Jean-Philippe, Dupieux, Céline, Morelec, Isabelle, Janier, Marc, Giammarile, Francesco, Tod, Michel, Gagnieu, Marie-Claude, Goutelle, Sylvain, and Mabrut, Eugénie
- Published
- 2015
- Full Text
- View/download PDF
91. In-depth immunophenotyping with mass cytometry during TB treatment reveals non-canonical T-cell subsets associated with sputum culture conversion
- Author
-
Chedid, Carole, primary, Andrieu, Thibault, additional, Kokhreidze, Eka, additional, Tukvadze, Nestani, additional, Biswas, Samanta, additional, Ather, Md. Fahim, additional, Uddin, Mohammad Khaja Mafij, additional, Banu, Sayera, additional, De Maio, Flavio, additional, Delogu, Giovanni, additional, Endtz, Hubert, additional, Goletti, Delia, additional, Vocanson, Marc, additional, Dumitrescu, Oana, additional, Hoffmann, Jonathan, additional, and Ader, Florence, additional
- Published
- 2021
- Full Text
- View/download PDF
92. Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study
- Author
-
Gaborit, Benjamin, primary, Dailly, Eric, additional, Vanhove, Bernard, additional, Josien, Régis, additional, Lacombe, Karine, additional, Dubee, Vincent, additional, Ferre, Virginie, additional, Brouard, Sophie, additional, Ader, Florence, additional, Vibet, Marie-Anne, additional, Le Thuaut, Aurélie, additional, Danger, Richard, additional, Flet, Laurent, additional, Omnes, Anne, additional, Berly, Laetitia, additional, Chiffoleau, Anne, additional, Jobert, Alexandra, additional, Duvaux, Odile, additional, and Raffi, François, additional
- Published
- 2021
- Full Text
- View/download PDF
93. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter?
- Author
-
van Summeren, Jojanneke, Meijer, Adam, Aspelund, Guðrún, Casalegno, Jean Sebastien, Erna, Guðrún, Hoang, Uy, Lina, Bruno, de Lusignan, Simon, Teirlinck, Anne C., Thors, Valtýr, Paget, John, Ouziel, Antoine, Tardy, Jean-claude, Gaucherand, Pascal, Massardier, Jerome, Polazzi, Stephanie, Duclos, Antoine, Benchaib, Mehdi, Cartier, Regine, Jourdain, Marine, Ottmann, Michelle, Kramer, Rolf, Fiorini, Sylvie, Rivat, Nathalie, Mekki, Yahia, Fort-Jacquier, Julie, Barral, Maud-Catherine, Noelie, Vey, Haesebaert, Julie, Horvat, Come, Vidoni, Leo, Reynes, Jean-Marc, Eleouet, Jean-Francois, Josset, Laurence, Receveur, Matthieu, Javouhey, Etienne, Ploin, Dominique, Valette, Martine, Fanget, Remi, Targe, Sandrine Couray, Myar-Dury, Anne-Florence, Doret-Dion, Muriel, Massoud, Mona, Masson, Elsa, Bard, Emilie, Queromes, Gregory, Vanhems, Phillipe, Claris, Olivier, Butin, Marine, Ader, Florence, Bin, Sylvie, Gaymard, Alexandre, Morfin, Florence, Gillet, Yves, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Directorate of Health [Reykjavík], Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL), Landspitali National University Hospital of Iceland, University of Oxford [Oxford], Children’s Hospital [Reykjavik, Iceland], University of Iceland [Reykjavik], This study is performed as a side project of the RSV ComNet study. The aim of the RSV ComNet project is to measure the disease burden of RSV in children aged ≤5 years in primary care, and is funded by Sanofi Pasteur and AstraZeneca., VRS study group in Lyon: Antoine Ouziel, Jean-claude Tardy, Pascal Gaucherand, Jerome Massardier, Stephanie Polazzi, Antoine Duclos, Mehdi Benchaib, Regine Cartier, Marine Jourdain, Michelle Ottmann, Rolf Kramer, Sylvie Fiorini, Nathalie Rivat, Yahia Mekki, Julie Fort-Jacquier, Maud-Catherine Barral, Vey Noelie, Julie Haesebaert, Come Horvat, Leo Vidoni, Jean-Marc Reynes, Jean-Francois Eleouet, Laurence Josset, Matthieu Receveur, Etienne Javouhey, Dominique Ploin, Martine Valette, Remi Fanget, Sandrine Couray Targe, Anne-Florence Myar-Dury, Muriel Doret-Dion, Mona Massoud, Elsa Masson, Emilie Bard, Gregory Queromes, Phillipe Vanhems, Olivier Claris, Marine Butin, Florence Ader, Sylvie Bin, Alexandre Gaymard, Florence Morfin, Yves Gillet, and Lyon, VRS study group in
- Subjects
Author's Correction ,0301 basic medicine ,Veterinary medicine ,viruses ,Iceland ,surveillance data ,MESH: Respiratory Syncytial Virus, Human ,Respiratory syncytial virus ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,MESH: Child ,Epidemiology ,MESH: COVID-19 ,030212 general & internal medicine ,Respiratory system ,Child ,virus diseases ,RSV ,respiratory system ,MESH: Iceland ,MESH: Infant ,Europe ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,epidemiology ,France ,Seasons ,Winter season ,Rapid Communication ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Surveillance data ,Coronavirus disease 2019 (COVID-19) ,COVID-19 pandemic ,Respiratory Syncytial Virus Infections ,Biology ,Virus ,03 medical and health sciences ,MESH: Respiratory Syncytial Virus Infections ,Virology ,medicine ,Humans ,MESH: SARS-CoV-2 ,MESH: Humans ,SARS-CoV-2 ,Public Health, Environmental and Occupational Health ,Small children ,COVID-19 ,Infant ,MESH: France ,030104 developmental biology ,Respiratory Syncytial Virus, Human ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,MESH: Europe ,MESH: Seasons - Abstract
International audience; Since the introduction of non-pharmacological interventions to control COVID-19, respiratory syncytial virus (RSV) activity in Europe has been limited. Surveillance data for 17 countries showed delayed RSV epidemics in France (≥ 12 w) and Iceland (≥ 4 w) during the 2020/21 season. RSV cases (predominantly small children) in France and Iceland were older compared with previous seasons. We hypothesise that future RSV epidemic(s) could start outside the usual autumn/winter season and be larger than expected. Year-round surveillance of RSV is of critical importance.
- Published
- 2021
94. Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference
- Author
-
Garreau, Romain, Bricca, Romain, Gagnieu, Marie-Claude, Roux, Sandrine, Conrad, Anne, Bourguignon, Laurent, Ferry, Tristan, Goutelle, Sylvain, Valour, Florent, Perpoint, Thomas, Miailhes, Patrick, Ader, Florence, Becker, Agathe, Triffault-Fillit, Claire, Pouderoux, Cécile, Benech, Nicolas, Chauvelot, Pierre, Perry, Marielle, Daoud, Fatiha, Lippman, Johanna, Braun, Evelyne, Chidiac, Christian, Servien, Elvire, Lustig, Sébastien, Batailler, Cécile, Gunst, Stanislas, Schmidt, Axel, Malatray, Matthieu, Sappey-Marinier, Elliot, Fessy, Michel-Henry, Viste, Anthony, Besse, Jean-Luc, Chaudier, Philippe, Louboutin, Lucie, Ode, Quentin, van Haecke, Adrien, Mercier, Marcelle, Belgaid, Vincent, Walch, Arnaud, Martres, Sébastien, Trouillet, Franck, Barrey, Cédric, Mojallal, Ali, Brosset, Sophie, Hanriat, Camille, Person, Hélène, Sigaux, Nicolas, Céruse, Philippe, Fuchsmann, Carine, Aubrun, Frédéric, Dziadzko, Mikhail, Macabéo, Caroline, Laurent, Frederic, Beraud, Laetitia, Roussel-Gaillard, Tiphaine, Dupieux, Céline, Kolenda, Camille, Josse, Jérôme, Brevet, Marie, Trecourt, Alexis, Craighero, Fabien, Boussel, Loic, Pialat, Jean-Baptiste, Morelec, Isabelle, Tod, Michel, Mabrut, Eugénie, Hospices Civils de Lyon (HCL), Lyon Bone and Joint Infection Study Group (BJI), Hôpital Nord-Ouest de Villefranche-sur-Saône, Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre interrégional de référence Rhône-Alpes - Auvergne des infections ostéo-articulaires complexes, Institut des Sciences Pharmaceutiques et Biologiques (ISPB), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Modeling & analysis for medical imaging and Diagnosis (MYRIAD), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL)
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Population ,MESH: Daptomycin ,03 medical and health sciences ,0302 clinical medicine ,Daptomycin ,Pharmacokinetics ,MESH: Drug Monitoring ,Internal medicine ,MESH: Anti-Bacterial Agents ,medicine ,polycyclic compounds ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Dosing ,education ,Pharmacology ,Volume of distribution ,Sex Characteristics ,education.field_of_study ,MESH: Humans ,medicine.diagnostic_test ,business.industry ,Drug interaction ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,bacterial infections and mycoses ,MESH: Rifampin ,MESH: Male ,Anti-Bacterial Agents ,Infectious Diseases ,Therapeutic drug monitoring ,Female ,Drug Monitoring ,Rifampin ,business ,MESH: Female ,Rifampicin ,medicine.drug ,MESH: Sex Characteristics - Abstract
Background Daptomycin is increasingly used in the treatment of bone and joint infection (BJI), but its pharmacokinetics (PK) and dosage requirements have not been thoroughly investigated in this indication. Daptomycin may be co-administered with rifampicin, which raises questions about a potential drug interaction. Objectives To investigate the population PK and dosage requirements of daptomycin in patients with BJI, and examine the influence of rifampicin co-administration. Methods A population approach was used to analyse PK data from patients who received daptomycin in our regional reference for BJI. We examined the influence of available covariates, including rifampicin co-administration on daptomycin PK. Simulations performed with the final model investigated the influence of dosages and covariates on PTA for both efficacy and safety. Results A total of 1303 daptomycin concentrations from 183 patients were analysed. A two-compartment model best described the data. Significant intra-individual variability was observed. Daptomycin clearance was influenced by renal function and sex, with females having a 26% lower typical clearance than males. Central volume of distribution (V1) was influenced by body weight, age, sex and rifampicin co-administration. Typical V1 was 11% lower in patients who were co-administered rifampicin. In PK/PD simulations, sex influenced the probability of AUC24/MIC target attainment, while rifampicin had a marginal effect. Conclusions A daptomycin dosage of 8 mg/kg/24 h in women and 10 mg/kg/24 h in men should optimize efficacy but may lead to excessive trough concentrations in many patients, especially in women. Therapeutic drug monitoring appears necessary for precision dosing of daptomycin.
- Published
- 2021
95. Pristinamycin in the treatment of MSSA bone and joint infection
- Author
-
Valour, Florent, Boibieux, André, Karsenty, Judith, Vallat, Marie-Paule, Braun, Evelyne, Perpoint, Thomas, Biron, François, Laurent, Frédéric, Lustig, Sébastien, Chidiac, Christian, Ferry, Tristan, Ader, Florence, Biron, François, Boibieux, André, Braun, Evelyne, Chidiac, Christian, Daoud, Fatiha, Ferry, Tristan, Gillet, Yves, Hees, Laure, Lippmann, Johanna, Miailhes, Patrick, Perpoint, Thomas, Roux, Sandrine, Saison, Julien, Vallat, Marie-Paule, Valour, Florent, Barrey, Cédric, Bérard, Jean-Baptiste, Boucher, Fabien, Breton, Pierre, Cantin, Olivier, Dalat, Frédéric, Desmarchelier, Romain, Fessy, Michel-Henry, Jacquesson, Timothée, Jouanneau, Emmanuel, Lustig, Sébastien, Mojallal, Ali, Neyret, Philippe, Peltier, Adrien, Reynaud, Olivier, Shipkov, Hristo, Signorelli, Francesco, Vermersch, Thibault, Viste, Anthony, Dupieux, Céline, Laurent, Frederic, Rasigade, Jean-Philippe, Vandenesch, François, Giammarile, Francesco, Janier, Marc, Morelec, Isabelle, Gagnieu, Marie-Claude, Goutelle, Sylvain, Tod, Michel, and Mabrut, Eugénie
- Published
- 2016
- Full Text
- View/download PDF
96. Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study
- Author
-
Chedid, Carole, Kokhreidze, Eka, Tukvadze, Nestani, Banu, Sayera, Uddin, Mohammad Khaja Mafij, Biswas, Samanta, Russomando, Graciela, Acosta, Chyntia Carolina Díaz, Arenas, Rossana, Ranaivomanana, Paulo PR., Razafimahatratra, Crisca, Herindrainy, Perlinot, Rakotonirina, Julio, Raherinandrasana, Antso Hasina, Rakotosamimanana, Niaina, Hamze, Monzer, Ismail, Mohamad Bachar, Bayaa, Rim, Berland, Jean-Luc, De Maio, Flavio, Delogu, Giovanni, Endtz, Hubert, Ader, Florence, Goletti, Delia, and Hoffmann, Jonathan
- Subjects
Adult ,Male ,Immunology ,Antitubercular Agents ,Enzyme-Linked Immunosorbent Assay ,inflammatory markers ,QuantiFERON ,Cohort Studies ,heparin-binding haemagglutinin adhesin ,treatment monitoring ,Interferon-gamma ,Treatment Outcome ,tuberculosis ,immunomonitoring ,Latent Tuberculosis ,Humans ,Immunology and Allergy ,Female ,Tuberculosis, Pulmonary ,Biomarkers ,Original Research ,interferon-gamma release assays - Abstract
Background Tuberculosis (TB) is a leading infectious cause of death. To improve treatment efficacy, quicker monitoring methods are needed. The objective of this study was to monitor the response to a heparin-binding hemagglutinin (HBHA) interferon-γ (IFN-γ) release assay (IGRA) and QuantiFERON-TB Gold Plus (QFT-P) and to analyze plasma IFN-γ levels according to sputum culture conversion and immune cell counts during treatment. Methods This multicentered cohort study was based in Bangladesh, Georgia, Lebanon, Madagascar, and Paraguay. Adult, non-immunocompromised patients with culture-confirmed pulmonary TB were included. Patients were followed up at baseline (T0), after two months of treatment (T1), and at the end of therapy (T2). Clinical data and blood samples were collected at each timepoint. Whole blood samples were stimulated with QFT-P antigens or recombinant methylated Mycobacterium tuberculosis HBHA (produced in Mycobacterium smegmatis; rmsHBHA). Plasma IFN-γ levels were then assessed by ELISA. Findings Between December 2017 and September 2020, 132 participants completed treatment, including 28 (21.2%) drug-resistant patients. rmsHBHA IFN-γ increased significantly throughout treatment (0.086 IU/ml at T0 vs. 1.03 IU/ml at T2, p < 0.001) while QFT-P IFN-γ remained constant (TB1: 0.53 IU/ml at T0 vs. 0.63 IU/ml at T2, p = 0.13). Patients with low lymphocyte percentages (79%) at baseline had significantly lower IFN-γ responses to QFT-P and rmsHBHA at T0 and T1. In a small group of slow converters (patients with positive cultures at T1; n = 16), we observed a consistent clinical pattern at baseline (high neutrophil percentages, low lymphocyte percentages and BMI, low TB1, TB2, and MIT IFN-γ responses) and low rmsHBHA IFN-γ at T1 and T2. However, the accuracy of the QFT-P and rmsHBHA IGRAs compared to culture throughout treatment was low (40 and 65% respectively). Combining both tests improved their sensitivity and accuracy (70–80%) but not their specificity (
- Published
- 2021
- Full Text
- View/download PDF
97. Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion
- Author
-
Genestet, Charlotte, primary, Hodille, Elisabeth, additional, Barbry, Alexia, additional, Berland, Jean-Luc, additional, Hoffmann, Jonathan, additional, Westeel, Emilie, additional, Bastian, Fabiola, additional, Guichardant, Michel, additional, Venner, Samuel, additional, Lina, Gérard, additional, Ginevra, Christophe, additional, Ader, Florence, additional, Goutelle, Sylvain, additional, and Dumitrescu, Oana, additional
- Published
- 2021
- Full Text
- View/download PDF
98. Interferon-[gamma] autoantibodies as predisposing factor for nontuberculous mycobacterial infection
- Author
-
Valour, Florent, Perpoint, Thomas, Senechal, Agathe, Kong, Xiao-Fei, Bustamante, Jacinta, Ferry, Tristan, Chidiac, Christian, and Ader, Florence
- Subjects
Bacterial infections -- Health aspects ,Biological response modifiers -- Health aspects ,Autoimmunity -- Health aspects ,Autoantibodies -- Health aspects ,Health - Abstract
Letter to the Editor To the Editor: Recent advances in the understanding of antimycobacterial immune response have led to descriptions of predisposing conditions to dissemination of nontuberculous mycobacteria (NTM) infection. [...]
- Published
- 2016
99. Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study
- Author
-
Delsuc, Claire, Cottereau, Aurélie, Frealle, Emilie, Bienvenu, Anne-Lise, Dessein, Rodrigue, Jarraud, Sophie, Dumitrescu, Oana, Le Maréchal, Marion, Wallet, Florent, Friggeri, Arnaud, Argaud, Laurent, Rimmelé, Thomas, Nseir, Saad, and Ader, Florence
- Published
- 2015
- Full Text
- View/download PDF
100. Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, Rhône Loire, France
- Author
-
Casalegno, Jean-Sebastien, Ploin, Dominique, Cantais, Aymeric, Masson, Elsa, Bard, Emilie, Valette, Martine, Fanget, Remi, Targe, Sandrine Couray, Myar-Dury, Anne-Florence, Doret-Dion, Muriel, Massoud, Mona, Queromes, Gregory, Vanhems, Philippe, Claris, Olivier, Butin, Marine, Pillet, Sylvie, Ader, Florence, Bin, Sylvie, Gaymard, Alexandre, Lina, Bruno, Morfin, Florence, Javouhey, Etienne, Gillet, Yves, Ouziel, Antoine, Tardy, Jean-claude, Gaucherand, Pascal, Panetta, Luc, Massardier, Jerome, Polazzi, Stephanie, Duclos, Antoine, Benchaib, Mehdi, Cartier, Regine, Jourdain, Marine, Ottmann, Michelle, Kramer, Rolf, Fiorini, Sylvie, Rivat, Nathalie, Mekki, Yahia, Fort-Jacquier, Julie, Barral, Maud-Catherine, Noelie, Vey, Haesebaert, Julie, Horvat, Come, Vidoni, Leo, Reynes, Jean-Marc, Eleouet, Jean-Francois, Josset, Laurence, Receveur, Matthieu, Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL), Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Virology and human respiratory Pathologies - Virology and human respiratory Pathologies (VirPath), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet - Saint-Étienne (UJM), Hôpital Edouard Herriot [CHU - HCL], Santé publique, épidémiologie et écologie évolutive des maladies infectieuses (PHE3ID), Pôle Information Médicale Evaluation Recherche (IMER), Hôpital de la Croix-Rousse [CHU - HCL], VRS study group in Lyon: Antoine Ouziel, Jean-claude Tardy, Pascal Gaucherand, Luc Panetta, Jerome Massardier, Stephanie Polazzi, Antoine Duclos, Mehdi Benchaib, Regine Cartier, Marine Jourdain, Michelle Ottmann, Rolf Kramer, Sylvie Fiorini, Nathalie Rivat, Yahia Mekki, Julie Fort-Jacquier, Maud-Catherine Barral, Vey Noelie, Julie Haesebaert, Come Horvat, Leo Vidoni, Jean-Marc Reynes, Jean-Francois Eleouet, Laurence Josset, Matthieu Receveur, Reynes, Jean-Marc, Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)
- Subjects
0301 basic medicine ,Pediatrics ,Epidemiology ,pharmacological interventions ,MESH: Hospitalization ,MESH: Respiratory Syncytial Virus, Human ,disease burden ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,MESH: Child ,030212 general & internal medicine ,Respiratory system ,Child ,Respiratory Tract Infections ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Respiratory tract infections ,Incidence (epidemiology) ,RSV ,MESH: Infant ,Hospitalization ,non-pharmacological interventions ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,bronchiolitis ,France ,Rapid Communication ,Adult ,medicine.medical_specialty ,Respiratory Syncytial Virus Infections ,Virus ,MESH: Respiratory Syncytial Virus Infections ,03 medical and health sciences ,Virology ,Lower respiratory tract infection ,medicine ,Humans ,Epidemics ,MESH: Epidemics ,Disease burden ,MESH: Humans ,business.industry ,SARS-CoV-2 ,Public Health, Environmental and Occupational Health ,Outbreak ,COVID-19 ,Infant ,MESH: Adult ,medicine.disease ,MESH: France ,030104 developmental biology ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Bronchiolitis ,Respiratory Syncytial Virus, Human ,MESH: Respiratory Tract Infections ,SARI ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
International audience; The Rhône-Loire metropolitan areas’ 2020/21 respiratory syncytial virus (RSV) epidemic was delayed following the implementation of non-pharmaceutical interventions (NPI), compared with previous seasons. Very severe lower respiratory tract infection incidence among infants ≤ 3 months decreased twofold, the proportion of cases among children aged > 3 months to 5 years increased, and cases among adults > 65 years were markedly reduced. NPI appeared to reduce the RSV burden among at-risk groups, and should be promoted to minimise impact of future RSV outbreaks.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.